Advancing the quality control methodology,,,to assess isolated total RNA,,,and generated fragmented cRNA
This Application Note describes how Gene Logic Inc. has improved itsability to analyze the quality of total RNA and fragmented cRNA by usingthe Agilent 2100 bioanalyzer. The Eukaryote Total RNA Nano and Picoassays are currently being utilized to examine the 28S/18S ratio
This Application Note describes how Gene Logic, Inc., has improved its
ability to analyze the quality of total RNA and fragmented cRNA by using
the Agilent 2100 bioanalyzer. The Eukaryote Total RNA Nano and Pico
assays are currently being utilized to examine the 28S/18S ratio in the
total RNA as well as detection of possible degradation. The mRNA Smear
Nano assay is used to confirm that a high percentage of the cRNA sample
is fragmented to lengths in the optimal range necessary to be hybridized
onto Affymetrix microarrays.
Gene Logic Inc. is a leading
provider of integrated genomics
information and bioinformatics
products and services related to
gene activity in human disease
and toxicity that enable global
pharmaceutical and biotechnology
companies to optimize the time,
risk and cost of drug discovery
and drug development. In order to
do this, the quality control methods
must ensure that only the
highest quality samples proceed
through our high-throughput
process, which in turn help to
reduce the downstream costs of
cDNA synthesis, In-Vitro Transcription
and, finally, hybridization
onto microarrays. For qualitative
purposes, many laboratories continue
to analyze their RNA samples
using MOPS gels with gel
electrophoresis. However, an
internet search of Microarray
facilities around the country
shows an increase in the usage of
the Agilent bioanalyzer.
When using gel electrophoresis to
examine the quality of samples,
pre-cast MOPS gels were used.
Every now and then a problem
with the gels was encountered,
either user related or gel related.
Some general problems occurring
were sample migration, mold
spots in the pre-cast gels and
staining difficulties. The key issue
associated with the RNA quality
control gel was that
'"/>Source:
Page: All 1 2 3 4 5 6 Related biology technology :1.
Using the Agilent 2100 bioanalyzer for
quality control of protein samples prior to
MS-analysis2.
Is Z factor the best assessment for the quality of cellular assays delivering higher content?3.
Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples4.
Quality control of antibodies using the
2100 bioanalyzer and the Protein 200
Plus assay5.
Homogeneous, chemiluminescent kinase assay kits for assessing the functional activity of a broad range of serine-threonine and tyrosine kinases6.
Easy preparation of total RNA from cultured cells with TRIzol and
Eppendorf Phase Lock Gel
(Date:11/20/2009)... TOLEDO recently announced that a free webinar, &l... At-Line Particle Characterization”, will be...the application of in situ particle characterizati...imize a series of roller compaction runs while var...ion forces. , (PRWEB) Nov...
(Date:11/19/2009)...able to charge their cell phones and other persona...discovery made by UC San Diego engineers could lea...uld do just this. , In recent research, publish..., a professor in the UCSD Department of Mechanical...udent Mark Hoefer, have found that artificially in...
(Date:11/19/2009)...wswire-FirstCall/ -- Omeros Corporation (Nasdaq: ... for the third quarter ended September 30, 2009. F...os reported a net loss of $3.9 million, or $1.34 p...n, or $2.54 per share, for the same period in 2008...e Company reported a net loss of $15.5 million, or...
(Date:11/19/2009)...Md., Nov. 19 Spherix Inc...hnology for diabetes therapy, and a provider of te..., supplement, biotechnology and pharmaceutical com...eported $6.3 million registered direct placement t...ts common stock and warrants to purchase up to 1,1...
Breaking Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2Nanotube defects equal better energy and storage systems 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3... of Gene Expression Signatures Derived by COXEN Al...to Current Treatments, OMAHA, Neb., and CHARLOTTE...ansgenomic (OTC Bulletin Board: TBIO) today announ...olecular diagnostic test which will guide,clinicia...ts for ovarian,cancer. The new test will be powere...
...t. 16 Intact Medical Corporation, an,emerging lea...invasive,systems for the diagnosis and removal of ...ed U.S. Food and Drug Administration (FDA) 510(k),...version of the Company,s,already FDA approved wand...,System (BLES). The Company expects to begin marke...
...6 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announ...l,data on RDEA594, its lead product candidate for ... on RDEA119,its lead mitogen-activated ERK kinase,...associated with gouty,arthritis, at the 2008 Ameri...CR) / Association of Rheumatology Health Professio...
Other Biology Technology:Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 2Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 3Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 4Intact Medical Corporation's Intact(R) Excise XL Receives 510(K) Marketing Clearance from the FDA 2Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting 2Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting 3(Date:11/20/2009)..., , NJIT researchers are at work on many scientif...ce Foundation has recently provided support that t...of the following investigators under the American ...researchers have been awarded grants for investiga...ished professor of physics, will enhance the capab...
(Date:11/20/2009)..., Researchers are invited to contribute their abs...(IOF WCO ECCEO10), the largest global meeting dev...itis research and patient care. The Congress will ... Beginning today, abstracts can be submitted onlin...ission deadline is February 4, 2010. , IOF and E...
(Date:11/20/2009)..., With the introduction of a single bacterial gen... Technology in the Netherlands achieved three impr...l waste material: ,More ethanol, less acetate and ... week the invention was published in the scientifi.... , Car fuel , Bioethanol is made by the yea...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Joint research into an enzyme that causes genetic diseases 9486 1Pinhead size worms + robot 3D new antibiotics 9481 1Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma 53737 1Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma 53737 2Zero Blunt TOPO PCR Cloning Kit for Sequencing with One Shot TOP10 Electrocomp E. coli from Invitrogen
Caspase-6 Inhibitor Z-VEID-FMK from BioVision
Human CCL21 / 6Ckine, Unconjugated, Fc Chimera from R&D Systems
QuantiChrom Zinc Assay Kit from BioAssay Systems
Biology Products: